Icagen to Present at the JP Morgan Healthcare Conference
04 janv. 2010 08h30 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 4, 2010 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced that executive management will participate in the 28th Annual JP Morgan Healthcare Conference...
Icagen to Present at the 63rd Annual Meeting of the American Epilepsy Society
01 déc. 2009 08h30 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Dec. 1, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced that data related to the Company's Phase I program for ICA-105665, the Company's lead drug...
Icagen Reports Receipt of Notification from NASDAQ Regarding Non-Compliance With Continued Listing Requirements
13 nov. 2009 16h30 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) reported today that on November 12, 2009 the Company received a notification from the NASDAQ Listing...
Icagen Reports Third Quarter 2009 Financial Results and Operational Highlights
05 nov. 2009 08h15 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 5, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) reported today its financial results and operational highlights for the third quarter ended September 30,...
Icagen Reports Top-line Results of Phase IIa Study of Senicapoc in Exercise-Induced Asthma
26 oct. 2009 16h30 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today reported that in a proof-of-concept, Phase IIa exercise-induced asthma study, senicapoc failed to...
Icagen to Report Third Quarter 2009 Results on November 5, 2009
26 oct. 2009 08h15 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced plans to release third quarter 2009 financial results on Thursday, November 5, 2009 before...
Icagen to Present at Eighth Annual Bio Investor Forum
20 oct. 2009 08h15 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced that executive management will participate in the Eighth Annual BIO Investor Forum to be held...
Icagen Describes Progress in Its Collaboration With Pfizer to Identify Selective Sodium Channel Inhibitors
19 oct. 2009 16h30 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced that data related to its collaboration with Pfizer focused on certain sodium channels for the...
Icagen Announces Initiation of Proof-of-Mechanism Study of ICA-105665 in Pain
28 sept. 2009 08h30 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 28, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced the initiation of a proof-of-mechanism study of ICA-105665 for the treatment of pain....
Icagen Announces Initiation of Proof-of-Concept Study of ICA-105665 in Photosensitive Epilepsy
24 sept. 2009 08h15 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 24, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced the initiation of a proof-of-concept study of ICA-105665 in patients with photosensitive...